⌕
Redhill Biopharma · RDHL · Nasdaq
Tenet — · withheld
Compare
$0.32−7.63%At close
$0.32−0.03 (−7.63%)
At close: Nov 19, 2026, 4:00 PM ET· Nasdaq · USD

Redhill Biopharma (RDHL) Earnings Forecast

What Wall Street expects this business to earn, and how much analysts disagree.

Sources Analyst estimates EstimatesConsensus as of How we compute thisNot investment advice
Consensus as of Nov 20, 2026 · we check it nightly
Forward P/E · FY26E
—
price ÷ consensus EPS
Revisions
Starts tonight
our record of this company begins Jul 10, 2026
Disagreement · FY26
—
high to low across the near-year panel
Coverage · FY26
0 · 1
EPS estimates · revenue estimates
Work out what the consensus implies at a multiple you chooseConsensus estimates only. Analysts' price forecasts and ratings are not licensed here.

Are estimates going up or down lately?

We hold no eps window in 90 days for FY26 yet. Every figure here compares one fiscal period at both ends.

No step line for this window yet. A line needs two nights of one fiscal period inside the window to join, and our record does not hold two.

EPS30 days90 daysshown aboveSince Jul 10
FY260 analystsNot yetour record does not hold 30 days of this periodNot yetour record does not hold 90 days of this periodNot yetour record does not reach back this far for this period
Dec '261 analyst◆ 0.0%$−352.86 to $−352.86▲ +25.6%$−474.29 to $−352.86▲ +25.6%$−474.29 to $−352.86
Mar '271 analyst5 of 30 days0.0% so far5 of 90 days0.0% so far◆ 0.0%$−474.29 to $−474.29

Measured between two of our own nightly snapshots of one fiscal period, so a new fiscal year entering the view is never read as a revision. Never backfilled. A window still filling says how many days it holds; a blank one means our record is not that long yet.

If the Street is right, what does that imply for the share price?

Price at last close · consensus as of Nov 20, 2026

Pick a fiscal year and a multiple and the sum runs on the numbers the Street published.

Consensus EPS · FY26
Not served
0 analysts · thin coverage
Multiple · yours
We hold no multiple of our own for this company, neither today's nor a fiscal-year record, so the multiple can only be yours.
Receipt · RDHL · FY26Nov 20, 2026
Implied, a share
Waiting

This is multiplication, not a forecast. It assumes the market pays the multiple you chose and that the consensus is right. Both are often wrong.

We hold no forward multiple for Redhill Biopharma today, so there is nothing here to set against the growth the Street expects.

Is next quarter a high bar or an easy one?

Analysts expect Redhill Biopharma to lose $352.86 a share in the December quarter, the one estimate published. We hold no expected date for the next report.

Expected report
Not held
No expected date is published for this company's next report, so none is printed here.
Revenue expected · December quarter
$24.3M
1 analyst, 24.3 to 24.3 in $M

For the March quarter, analysts expect a loss of $474.29 a share.

Does Redhill Biopharma usually beat or miss?

We have not been able to check a quarter yet. Our record of estimates for Redhill Biopharma begins on Jul 10, 2026, and a quarter can be checked only when we hold an estimate for it from before the company reported.

We started recording estimates on Jul 10, 2026, so quarters that reported before that date cannot be checked.

Our record, one quarter per report
Dec '26not reported yet
Mar '27
Jun '27
Sep '27
Dec '27
Mar '28
Jun '28
Sep '28
Dec '28
Mar '29
Jun '29
Sep '29
Checked so far
None yet
one more every report
Beat expectations
Nothing to count
scores begin at the next report
Share price reaction
Not held
there is no checked quarter to measure a reaction for
Typical gap vs estimate
Not yet
shown once 4 quarters are checked

Checked against the company's reported figure (GAAP) and the average estimate we recorded the night before its results release. Where analysts' number is on an adjusted basis, we leave the comparison out rather than force it. We started recording estimates for Redhill Biopharma on Jul 10, 2026, so earlier quarters cannot be checked, and we never fill them in after the fact.

0 analysts publish an EPS estimate for FY26 and 1 publishes revenue. Consensus figures are on the Street's basis and filed figures are GAAP; we label the gap, we do not explain it away.Show coverage by year and over timeHide the coverage chart
Analysts by fiscal year · outlined revenue, filled EPS. Amber marks a panel of fewer than 15.
10
FY26E
The FY26 panel has held 0 analysts every night since our record of it began on Jul 10, 2026.

The full consensus, year by year

Consensus as of Nov 20, 2026 · filed figures as reported
Revenue · $Bfiled · consensus average · band = low to high
−0.00.00.1historyStreet forecastFY22FY25FY26E

Coverage thins with distance: 1 revenue estimates for FY26, 1 for FY26.

Diluted EPS · $filed · consensus average · band = low to high
Not enough estimate history to chart yet.

Out-year bands widen as fewer analysts publish: 0 EPS estimates for FY26, 0 for FY26.

Fiscal yearRevenue $BYoYEPS $YoYEBITDA $BNet inc. $BShares BAnalysts rev · EPSFwd P/E
FY25Filed0.0—0.00————as filed—
FY26E0.10.1 to 0.1▲17592.3%a—n/ca———1 · 0—

Average estimate with low to high beneath. Amber counts mark thin coverage and thin rows carry an amber rule. Shares = consensus net income ÷ consensus EPS, a direction rather than a decimal. The filed row's last column is today's price over that year's filed EPS, the one trailing multiple in that column. a This step crosses the seam: last year is a filed GAAP actual and this year is a consensus estimate, so the two are not prepared on one basis. b More than a third of the analyst panel changed between these two years, so the difference of the two averages measures the panel rather than the forecast.

These are consensus estimates: what analysts expect the business to earn, not where they think the stock trades. Coverage thins and the low to high band widens in the out-years. Context, not advice.

Analysts' price forecasts and grades are not licensed here. This page shows forward consensus estimates only: 0 EPS estimates for FY26, 1 for revenue. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.